Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 4
2015 2
2016 8
2017 4
2018 9
2019 10
2020 11
2021 4
2022 11
2023 9
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

67 results

Results by year

Filters applied: . Clear all
Page 1
Renal cell carcinoma histologic subtypes exhibit distinct transcriptional profiles.
Barata P, Gulati S, Elliott A, Hammers HJ, Burgess EF, Gartrell BA, Darabi S, Bilen MA, Basu A, Geynisman DM, Dawson NA, Zibelman MR, Zhang T, Wei S, Ryan CJ, Heath EI, Poorman KA, Nabhan C, McKay RR. Barata P, et al. Among authors: zibelman mr. J Clin Invest. 2024 Apr 23:e178915. doi: 10.1172/JCI178915. Online ahead of print. J Clin Invest. 2024. PMID: 38652565 Free article.
Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide.
Parikh M, Tangen C, Hussain MHA, Gupta S, Callis S, Jo Y, Harzstark A, Paller CJ, George S, Zibelman MR, Cheng HH, Maughan BL, Zhang J, Pachynski RK, Bryce AH, Lin DW, Quinn DI, Lerner SP, Thompson IM, Dorff TB, Lara PN, Agarwal N. Parikh M, et al. Among authors: zibelman mr. Eur Urol Oncol. 2024 Mar 23:S2588-9311(24)00054-3. doi: 10.1016/j.euo.2024.03.001. Online ahead of print. Eur Urol Oncol. 2024. PMID: 38523017 Free article.
NCCN Guidelines® Insights: Kidney Cancer, Version 2.2024.
Motzer RJ, Jonasch E, Agarwal N, Alva A, Bagshaw H, Baine M, Beckermann K, Carlo MI, Choueiri TK, Costello BA, Derweesh IH, Desai A, Ged Y, George S, Gore JL, Gunn A, Haas N, Johnson M, Kapur P, King J, Kyriakopoulos C, Lam ET, Lara PN, Lau C, Lewis B, Madoff DC, Manley B, Michaelson MD, Mortazavi A, Ponsky L, Ramalingam S, Shuch B, Smith ZL, Sosman J, Sweis R, Zibelman M, Schonfeld R, Stein M, Gurski LA. Motzer RJ, et al. Among authors: zibelman m. J Natl Compr Canc Netw. 2024 Feb;22(1):4-16. doi: 10.6004/jnccn.2024.0008. J Natl Compr Canc Netw. 2024. PMID: 38394781
A phase 1 study of nivolumab in combination with interferon-gamma for patients with advanced solid tumors.
Zibelman M, MacFarlane AW 4th, Costello K, McGowan T, O'Neill J, Kokate R, Borghaei H, Denlinger CS, Dotan E, Geynisman DM, Jain A, Martin L, Obeid E, Devarajan K, Ruth K, Alpaugh RK, Dulaimi EA, Cukierman E, Einarson M, Campbell KS, Plimack ER. Zibelman M, et al. Nat Commun. 2023 Jul 27;14(1):4513. doi: 10.1038/s41467-023-40028-z. Nat Commun. 2023. PMID: 37500647 Free PMC article. Clinical Trial.
Flutamide With or Without PROSTVAC in Non-metastatic Castration Resistant (M0) Prostate Cancer.
Madan RA, Bilusic M, Stein MN, Donahue RN, Arlen PM, Karzai F, Plimack E, Wong YN, Geynisman DM, Zibelman M, Mayer T, Strauss J, Chen G, Rauckhorst M, McMahon S, Couvillon A, Steinberg S, Figg WD, Dahut WL, Schlom J, Gulley JL. Madan RA, et al. Among authors: zibelman m. Oncologist. 2023 Jul 5;28(7):642-e561. doi: 10.1093/oncolo/oyad058. Oncologist. 2023. PMID: 37134294 Free PMC article. Clinical Trial.
A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy.
Jang HJ, Hostetter G, Macfarlane AW, Madaj Z, Ross EA, Hinoue T, Kulchycki JR, Burgos RS, Tafseer M, Alpaugh RK, Schwebel CL, Kokate R, Geynisman DM, Zibelman MR, Ghatalia P, Nichols PW, Chung W, Madzo J, Hahn NM, Quinn DI, Issa JJ, Topper MJ, Baylin SB, Shen H, Campbell KS, Jones PA, Plimack ER. Jang HJ, et al. Among authors: zibelman mr. Clin Cancer Res. 2023 Jun 1;29(11):2052-2065. doi: 10.1158/1078-0432.CCR-22-3642. Clin Cancer Res. 2023. PMID: 36928921 Free PMC article. Clinical Trial.
Global Meta-analysis of Urine Microbiome: Colonization of Polycyclic Aromatic Hydrocarbon-degrading Bacteria Among Bladder Cancer Patients.
Bukavina L, Isali I, Ginwala R, Sindhani M, Calaway A, Magee D, Miron B, Correa A, Kutikov A, Zibelman M, Ghannoum M, Retuerto M, Ponsky L, Markt S, Uzzo R, Abbosh P. Bukavina L, et al. Among authors: zibelman m. Eur Urol Oncol. 2023 Apr;6(2):190-203. doi: 10.1016/j.euo.2023.02.004. Epub 2023 Mar 1. Eur Urol Oncol. 2023. PMID: 36868921
Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors.
Rudin CM, Pandha HS, Zibelman M, Akerley WL, Harrington KJ, Day D, Hill AG, O'Day SJ, Clay TD, Wright GM, Jennens RR, Gerber DE, Rosenberg JE, Ralph C, Campbell DC, Curti BD, Merchan JR, Ren Y, Schmidt EV, Guttman L, Gupta S. Rudin CM, et al. Among authors: zibelman m. J Immunother Cancer. 2023 Jan;11(1):e005007. doi: 10.1136/jitc-2022-005007. J Immunother Cancer. 2023. PMID: 36669791 Free PMC article. Clinical Trial.
67 results